Investigational drug · Phase 3
CMP 001
Also called: Vidutolimod
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Malignancies, NSCLC, Ovarian Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
1
Any phase or sponsor naming "CMP 001"
First trial start
2021
Sep 29, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CMP 001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Malignancies
- NSCLC
- Ovarian Cancer
- Urothelial Cancer
- Solid Tumors
- Locally Advanced Basal Cell Carcinoma
Approved drugs for the same conditions: Non-small cell lung cancer · Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "CMP 001" as an intervention, largest first.
- Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingPivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT05059522 · 77 participants · Start Sep 29, 2021 · Primary completion Dec 31, 2026
Drug: Avelumab; Lorlatanib and 6 more · For: Advanced Malignancies; NSCLC; Ovarian Cancer and 2 more
Sites: Fayetteville, Arkansas; Rogers, Arkansas; Springdale, Arkansas · 71 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Immunogenicity assessment for vidutolimod: a risk-driven approach for a simplified 1-tiered, singlicate anti-drug antibody testing strategy.
Valentine JL, Shank S, Fred Lucena LM, et al. · Front Immunol 2026
- Intratumoral Virus-Like Particles Containing a TLR9 Agonist Combined with Systemic αPD-1 Activate Tumor-Specific CD8+ T Cells.
Fischer TD, Lemke-Miltner CD, Weiner GJ · Cancer Res Commun 2026
- BDCA2 plays a central role in the binding, internalization and response of plasmacytoid dendritic cells to vidutolimod.
Lemke-Miltner CD, Blackwell SE, Yin C, et al. · Front Immunol 2026
- Correction to "Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study".
· Cancer 2025
- In vitro characterization of cellular responses elicited by endosomal TLR agonists encapsulated in Qβ virus-like particles.
Hasibuzzaman MM, Ibarra B, Khan IN, et al. · BMC Immunol 2025
- Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study.
Milhem MM, Zakharia Y, Davar D, et al. · Cancer 2025
Also in development for Advanced Malignancies
- LBL-007AlcestobartPhase 38 trials
BeOne Medicines (BeiGene) · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer
- GimistotugBGB-A445Phase 34 trials
BeOne Medicines (BeiGene) · Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma
- PelabresibDAK539, CPI-0610Phase 34 trials
Novartis · Myelofibrosis, Primary Myelofibrosis, Primary Myelofibrosis (PMF)
- TQB2930Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · HER2-positive Advanced Breast Cancer, Colorectal Cancer, Metastatic Breast Cancer
- TQB3616Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
- BGB-15025Phase 33 trials
BeOne Medicines (BeiGene) · Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Advanced Malignancies
- SurzebiclimabBGB-A425Phase 33 trials
BeOne Medicines (BeiGene) · Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion, NSCLC for Phase 2 Dose Expansion
- OciperlimabBGB-A1217Phase 32 trials
BeOne Medicines (BeiGene) · Non Small Cell Lung Cancer, Advanced Malignancies
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.